Clinical trial
An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)
NCT05517980 is registered in ClinicalTrials.gov with Kira Pharmacenticals (US), LLC. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)
- Lead sponsor
- Kira Pharmacenticals (US), LLC.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 31, 2025
- Completion date
- April 30, 2027
- Enrollment
- 52 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.